Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of "Moderate Buy" by Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine research firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $19.63.

Several brokerages have issued reports on STOK. Cantor Fitzgerald reiterated an "overweight" rating on shares of Stoke Therapeutics in a research note on Thursday. Wedbush lifted their price objective on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the company an "outperform" rating in a research report on Tuesday, March 26th. JPMorgan Chase & Co. lifted their price objective on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the company a "neutral" rating in a research report on Tuesday, March 26th. HC Wainwright reissued a "buy" rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, March 26th. Finally, TD Cowen raised shares of Stoke Therapeutics from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 26th.

Stoke Therapeutics Price Performance

STOK stock traded up $0.40 during midday trading on Friday, hitting $12.57. The company's stock had a trading volume of 634,950 shares, compared to its average volume of 2,698,084. Stoke Therapeutics has a twelve month low of $3.35 and a twelve month high of $16.40. The company's fifty day moving average price is $7.21 and its 200 day moving average price is $5.41. The stock has a market capitalization of $582.04 million, a P/E ratio of -5.30 and a beta of 0.77.

Insider Buying and Selling

In related news, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $4.80, for a total transaction of $48,000.00. Following the completion of the sale, the insider now owns 6,981 shares of the company's stock, valued at approximately $33,508.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Stoke Therapeutics news, CFO Stephen J. Tulipano sold 4,116 shares of Stoke Therapeutics stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $6.10, for a total value of $25,107.60. Following the completion of the sale, the chief financial officer now owns 20,746 shares in the company, valued at approximately $126,550.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $4.80, for a total transaction of $48,000.00. Following the completion of the sale, the insider now owns 6,981 shares of the company's stock, valued at approximately $33,508.80. The disclosure for this sale can be found here. In the last 90 days, insiders sold 32,741 shares of company stock valued at $223,115. Company insiders own 12.30% of the company's stock.

Institutional Trading of Stoke Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of STOK. Ensign Peak Advisors Inc acquired a new stake in Stoke Therapeutics in the 1st quarter worth about $25,000. Point72 Hong Kong Ltd acquired a new position in shares of Stoke Therapeutics in the 1st quarter valued at approximately $27,000. Great West Life Assurance Co. Can raised its position in shares of Stoke Therapeutics by 46.7% in the 1st quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company's stock valued at $28,000 after buying an additional 1,078 shares in the last quarter. Dorsey & Whitney Trust CO LLC acquired a new position in shares of Stoke Therapeutics in the 3rd quarter valued at approximately $43,000. Finally, UBS Group AG acquired a new position in shares of Stoke Therapeutics in the 3rd quarter valued at approximately $47,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.